Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Re V, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infectious Diseases 2015, 2: ofv109. PMID: 26284259, PMCID: PMC4536329, DOI: 10.1093/ofid/ofv109.Peer-Reviewed Original ResearchEnd-stage liver diseaseHIV/HCV-coinfected patientsRisk of ESLDHIV/HCV patientsHuman immunodeficiency virusFIB-4Antiretroviral therapyESLD riskHCV patientsLaboratory variablesLiver diseaseHuman immunodeficiency virus/hepatitis C virus‐coinfected patientsHepatitis C virus-coinfected patientsLiver-related deathRetrospective cohort studyRisk factor modificationPlatelet ratio indexDecision curve analysisVeterans Health AdministrationHCV treatment decisionsHepatic decompensationHCV treatmentCohort studyCox regressionImmunodeficiency virus